Comprehend Systems
has added new features and functionalities to its clinical data visualization and analytics software, Comprehend Clinical™, offering clinical developers unparalleled access to research data within individual trials and across multiple studies in a category or pipeline.
Comprehend Clinical is a visualization and analytics tool created by industry veterans with a mission to help sponsors and CROs overcome key obstacles in clinical development. Comprehend Clinical is easy to deploy, use, and integrate with other systems, including electronic data capture (EDC) and clinical trial management (CTMS). With simple, embeddable and interactive dashboards, Comprehend Clinical enables ad-hoc reporting from any data source in real-time. As a result, Comprehend Clinical offers a view into the most critical high-level operational metrics – from patient recruitment toserious adverse events – as well as the ability to drill down into specific issues that arise throughout the course of a trial – from protocol deviations to problematic sites.
Using Comprehend Clinical, CROs are able to provide their customers with better access to their data, and EDC vendors can supplement their offering with best-in-show analytics. New features in Comprehend Clinical include:
· Mobile access – Comprehend Clinical dashboards are now functional on web-enabled mobile devices, including smart phones and the iPad, and can be embedded on any web portal or SharePoint site.
· Drag-and-drop ad-hoc reporting – Users can quickly create more complex visualizations and customized, real-time reports.
· Custom dashboards – Dashboards can be customized by the user to ensure they are getting up-to-date access to the data that is most important to them and drill down as necessary.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.